Abstract
A role for p53 in the in vivo progression of Friend virus-induced erythroleukemia has been suggested but not clearly defined. We developed a Friend virus-sensitive, p53-deficient mouse model to directly address the role of p53 in Friend erythroleukemia. When infected with the polycythemia-inducing strain of Friend virus (FVP), p53 null mice exhibited accelerated progression to erythroleukemia and accelerated death following diagnosis when compared to wild type mice. Confirmation that p53 mutations were required for disease progression was provided by sequence analysis of p53 transcripts in leukemic wild type and heterozygous mice. All transcripts evaluated had point mutations, deletions or insertions in the p53 gene. The ability to grow tumor colonies in vitro and derive cell lines was enhanced in FVP-infected p53 null animals. Although PU.1 oncogene overexpression is a common mutation observed in cell lines derived from Friend virus-infected p53 wild type mice, it was not a universal finding in cell lines derived from p53 null animals. Our data conclusively demonstrate that loss of p53 function is a requirement for progression of Friend erythroleukemia in vivo. Further, the data demonstrate that erythroleukemias arising in Friend virus-infected p53 null mice are biologically and genetically distinct from those that occur in wild type animals, suggesting that the temporal order of PU.1 and p53 mutations is an important parameter in the pathogenesis of leukemic development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Barnache S, Wendling F, Lacombe C, Denis N, Titeux M, Vainchenker W, Moreau-Gachelin F . 1998 Oncogene 16: 2989–2995
Ben-David Y, Bernstein A . 1991 Cell 66: 831–834
Ben David Y, Prideaux VR, Chow V, Benchimol S, Bernstein A . 1988 Oncogene 3: 179–185
Chow V, Ben-David Y, Bernstein A, Benchimol S, Mowat M . 1987 J. Virol. 61: 2777–2781
de Stanchina E, McCurrach ME, Zindy F, Shieh S-Y, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW . 1998 Genes Dev. 12: 2434–2442
Donehower LA . 1996 Semin. Cancer Biol. 7: 269–278
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr. CA, Butel JS, Bradley A . 1992 Nature 356: 215–221
Hainaut P, Hollstein M . 2000 Adv. Cancer Res. 77: 81–137
Harvey M, McArthur MJ, Montgomery Jr. CA, Bradley A, Donehower LA . 1993 FASEB J. 7: 938–943
Hicks GG, Mowat M . 1988 J. Virol. 62: 4752–4755
Hofer E, Darnell Jr. JE . 1981 Cell 23: 585–593
Howard J, Ung Y, Adachi D, Ben-David Y . 1996 Cell Growth Differ. 7: 1651–1660
Howard JC, Yousefi S, Cheong G, Bernstein A, Ben-David Y . 1993 Oncogene 8: 2721–2729
Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA . 1994 Curr. Biol. 4: 1–7
Johnson P, Chung S, Benchimol S . 1993 Mol. Cell. Biol. 13: 1456–1463
Kelley LL, Hicks GG, Hsieh FF, Prasher JM, Green WF, Miller MD, Eide EJ, Ruley HE . 1998 Oncogene 17: 1119–1130
Khanna KK . 2000 J. Natl. Cancer Inst. 92: 795–802
Koury MJ, Park DJ, Martincic D, Horne DW, Kravtsov V, Whitlock JA, del Pilar Aguinaga M, Kopsombut P . 1997 Blood 90: 4054–4061
Lavigueur A, Bernstein A . 1991 Oncogene 6: 2197–2201
Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A . 1989 Mol. Cell. Biol. 9: 3982–3991
Li J-P, D'Andrea AD, Lodish HF, Baltimore D . 1990 Nature 343: 762–764
Li J-P, Hu H-O, Niu Q-T, Fang C . 1995 J. Virol. 69: 1714–1719
Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tisty TD . 1992 Cell 70: 923–935
Mager DL, Mak TW, Bernstein A . 1981 Proc. Natl. Acad. Sci. 78: 1703–1707
Moreau-Gachelin F, Ray D, de Both NJ, van der Feltz MJM, Tambourin P, Tavitian A . 1990 Leukemia 4: 20–23
Moreau-Gachelin F, Ray D, Mattei M-G, Tambourin P, Tavitian A . 1989 Oncogene 4: 1457–1462
Moreau-Gachelin F, Tavitian A, Tambourin P . 1988 Nature 331: 277–280
Moreau-Gachelin F, Wendling F, Molina T, Denis N, Titeux M, Grimber G, Briand P, Vainchenker W, Tavitian A . 1996 Mol. Cell. Biol. 16: 2453–2463
Mowat M, Cheng A, Kimura N, Bernstein A, Benchimol S . 1985 Nature 314: 633–636
Munroe DG, Peacock JW, Benchimol S . 1990 Mol. Cell. Biol. 10: 3307–3313
Munroe DG, Rovinski B, Bernstein A, Benchimol S . 1988 Oncogene 2: 621–624
Ney PA, D'Andrea AD . 2000 Blood 96: 3675–3680
Palmero I, Pantoja C, Serrano M . 1998 Nature 395: 125–126
Paul R, Schuetze S, Kozak SL, Kabat D . 1989 J. Virol. 63: 4958–4961
Prives C . 1998 Cell 95: 5–8
Quang CT, Wessely O, Pironin M, Beug H, Ghysdael J . 1997 EMBO. J. 16: 5639–5653
Ray D, Bosselut R, Ghysdael J, Mattei M-G, Tavitian A, Moreau-Gachelin F . 1992 Mol. Cell. Biol. 12: 4297–4304
Rovinski B, Munroe D, Peacock J, Mowat M, Bernstein A, Benchimol S . 1987 Mol. Cell. Biol. 7: 847–853
Ryan JJ, Danish R, Gottlieb CA, Clarke MF . 1993 Mol. Cell. Biochem. 13: 711–719
Schuetze S, Stenberg PE, Kabat D . 1993 Mol. Cell. Biol. 13: 5670–5678
Sherr CJ . 1998 Genes Dev. 12: 2984–2991
Shibuya T, Mak TW . 1982 Cell 31: 483–493
Silver J, Kozak C . 1986 J. Virol. 57: 526–533
Soussi T . 2001 Ann. NY Acad. Sci 121–139
Tambourin PE, Gallien-Lartigue O, Wendling F, Huaulme D . 1973 Br. J. Haematol. 24: 511–524
Wong KS, Li Y-J, Howard J, Ben-David Y . 1999 Oncogene 18: 5525–5534
Yamada T, Kondoh N, Matsumoto M, Yoshida M, Maekawa A, Oikawa T . 1997 Blood 89: 1383–1393
Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF . 1998 Genes Dev. 12: 2424–2433
Acknowledgements
We would like to thank Dr. Sandra Ruscetti, National Cancer Institute, Frederick, MD, USA for generally sharing reagents, protocols and advice regarding the study. This work was supported by an IRG from the American Cancer Society, The Primary Children's Medical Center Research Foundation, and NIH P50DK49219 (Center of Excellence in Molecular Hematology) to LL Kelley and NIH CA83984-01 to KSJ Elenitora-Johnson.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Prasher, J., Elenitoba-Johnson, K. & Kelley, L. Loss of p53 tumor suppressor function is required for in vivo progression of Friend erythroleukemia. Oncogene 20, 2946–2955 (2001). https://doi.org/10.1038/sj.onc.1204395
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204395